Why the study?
As cancer survival improves, cancer therapy-related cardiovascular toxicity has become increasingly prominent, yet available treatments to ameliorate this toxicity remain very limited.
Design
Review
Authors
Loading...
Rising CTR-CVT burden in cancer survivors warrants cardio-oncology vigilance; leaves open optimal prevention strategies for prospective trials.
This review outlines the mechanisms of anticancer drug-induced cardiotoxicity and identifies mitochondrial transplantation as a promising emerging therapeutic strategy.
Gao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: